Wu et al. reported a higher proportion of CHEK2 c.1100delC carriers in men with lethal prostate cancer (1.28%) compared with those with low-risk disease (0.16%) [19], but Leongamornlert et al. observed that only “non-1100delC” protein-truncating variants contributed to the aggressive form of the disease [12]. The gene discussed is CHEK2; the disease is prostate cancer.